Survival improvements were noted in brain and nervous system cancers, colorectal cancers, and lung cancer.
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The combination produced 2 complete responses.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
The Michigan Oncology Sequencing Program involved patients with advanced solid tumors who underwent next-generation sequencing to identify variants and potentially guide treatment.
A team of investigators sought to assess cardiac safety data associated with the use of doxorubicin in patients with soft tissue sarcomas.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
SBRT of all known metastatic sites was associated with improved PFS and OS among children and young adult patients with inoperable sarcoma.
Nivolumab plus ipilimumab demonstrated antitumor activity among patients with either primary or secondary angiosarcoma, according to phase 2 data.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Radioresistant sarcoma may require treatment intensification.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.